文献速递瓣膜病与结构性心脏病

靶向1-磷酸鞘氨醇信号预防主动脉瓣疾病进展

Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease.
PubMed 文献 · Circulation · 2024-10-21

该研究在小鼠线损伤诱导的主动脉瓣疾病模型中,通过药物和遗传手段调控S1P的生成、降解及受体信号,发现升高S1P水平加重瓣膜钙化和心功能损害,而SphK1缺陷或S1PR2抑制则减轻疾病进展;机制上S1P/S1PR2通过RUNX2/OPG和GSK3β-Wnt-β-catenin通路促进瓣膜间质细胞成骨分化和钙化,人狭窄瓣膜在高剪切应力下S1P含量和SphK1表达增高。

要点

  • 升高S1P水平加重主动脉瓣疾病进展和心功能损害。
  • S1PR2抑制或SphK1缺陷可减轻瓣膜钙化和疾病进展。
  • S1P/S1PR2通过RUNX2/OPG和GSK3β-Wnt-β-catenin通路促钙化。

核心结论

  • 全身或局部S1P水平升高导致瓣膜钙化增加。
  • S1PR2拮抗剂和SphK1抑制剂可能作为人类主动脉瓣疾病的预防、疾病修饰或防复发药物途径。

研究设计与样本

  • 小鼠线损伤诱导的主动脉瓣疾病模型,联合药物和遗传调控S1P生成、降解及受体信号。
  • 采用液相色谱-质谱法测定S1P。
  • 分析人瓣膜间质细胞钙化及对生物力学应激的响应。
  • 分析接受主动脉瓣置换患者离体主动脉瓣的S1P含量及心血管磁共振成像。

主要发现

  • 药物抑制S1P唯一降解酶S1P裂解酶升高S1P浓度,大幅加重小鼠主动脉瓣疾病进展并损害心功能。
  • SphK1缺陷所致的低S1P水平有效减轻主动脉瓣疾病进展。
  • S1PR2缺陷小鼠免于主动脉瓣疾病进展及高S1P导致的恶化。
  • 线损伤后给予药物S1PR2抑制成功预防主动脉瓣疾病发生。
  • 生物力学牵张通过SphK1刺激人瓣膜间质细胞产生S1P(以C17-S1P生成衡量),S1P/S1PR2信号通过成骨RUNX2/OPG信号和GSK3β-Wnt-β-catenin通路诱导成骨分化和钙化。

临床怎么用

  • S1PR2拮抗剂和SphK1抑制剂可能作为人类主动脉瓣疾病的预防、疾病修饰或防复发药物途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic valve disease (AVD) is associated with high mortality and morbidity. To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in osteogenic signaling, we examined the role of S1P signaling in aortic stenosis disease. METHODS: AVD progression and its consequences for cardiac function were examined in a murine wire injury-induced AVD model with and without pharmacological and genetic modulation of S1P production, degradation, and receptor signaling. S1P was measured by liquid chromatography-mass spectrometry. Calcification of human valvular interstitial cells and their response to biomechanical stress were analyzed in the context of S1P signaling. Human explanted aortic valves from patients undergoing aortic valve replacement and cardiovascular magnetic resonance imaging were analyzed for S1P by liquid chromatography-mass spectrometry. RESULTS: Raising S1P concentrations in mice with injury-induced AVD by pharmacological inhibition of its sole degrading enzyme S1P lyase vastly enhanced AVD progression and impaired cardiac function resembling human disease. In contrast, low S1P levels caused by SphK1 (sphingosine kinase 1) deficiency potently attenuated AVD progression. We found S1P/S1PR2 (S1P receptor 2) signaling to be responsible for the adverse S1P effect because S1PR2-deficient mice were protected against AVD progression and its deterioration by high S1P. It is important to note that pharmacological S1PR2 inhibition administered after wire injury successfully prevented AVD development. Mechanistically, biomechanical stretch stimulated S1P production by SphK1 in human valvular interstitial cells as measured by C17-S1P generation, whereas S1P/S1PR2 signaling induced their osteoblastic differentiation and calcification through osteogenic RUNX2/OPG signaling and the GSK3β-Wnt-β-catenin pathway. In patients with AVD, stenotic valves exposed to high wall shear stress had higher S1P content and increased SphK1 expression. CONCLUSIONS: Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Benkhoff M, Barcik M, Mourikis P, et al. Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease. Circulation. 2024. PMID: 39429140. doi:10.1161/CIRCULATIONAHA.123.067270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。